N/A N=77 Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
Prostate Cancer
Primary: Acute Grade 3 or Higher Treatment-related Toxicity Rate. — 1; 3 participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=356 A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
Post Menopausal Osteoporosis
Primary: Percentage of Participants Who Preferred Ibandronate Monthly Dosing to Risedronate Weekly Dosing — 81.7; 78.2; 79.9 percentage of participants — p=<0.0001
N/A N=120 Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
Carotid Artery Diseases · Stroke
Primary: The Rate of Peri-procedural (Within 30 Days of Procedure) Death, Stroke, and Myocardial Infarction. — 4 participants
Phase 4 N=19 The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia
Sleep Disorders · Fibromyalgia · Sleep
Primary: Number of Awakenings After Sleep Onset (NAASO) — 39.5; 34.9 Awakenings — p=0.424
Phase 2 N=202 Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers
HIV Infection · Rotavirus Infection
Primary: Percentage of Participants Developing New Grade >=3 Adverse Events — 1.6; 4.7; 13.5; 12.8 Percentage of participants — p=0.62
Early Phase 1 N=25 The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery
Infection
Primary: Circulating Vancomycin Concentration — 15.6 µg/mL — p=<0.0001
Phase 2 N=1,307 A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
Urologic Diseases · Urinary Bladder Diseases · Urological Manifestations
Primary: Change From Baseline to End of Treatment (EOT) in Mean Volume Voided Per Micturition — 14.0; 24.9; 34.5; 36.4 mL — p=0.97
Phase 4 N=16 Pathophysiology of Post Amputation Pain
Amputation Stumps · Neuroma
Primary: Change in Pain — -0.3; -2; -1; 1.3 units on a scale
N/A N=372 Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System (ISO/FDA Study)
Diabetes
Primary: Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15 mg/dL (<100 mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method — 317 Blood…
Phase 3 N=89 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic Response Rate — 55.9; 69.1 percentage of participants
Phase 3 N=162 A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Prostate Cancer
Primary: The Rate of Suppression of Serum Testosterone to Castrate Level — 81; 78; 0; 1 Participants
Phase 3 N=140 An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
Hepatitis · Hepatitis C · Hepatitis C/ Human Immunodeficiency Virus Coinfection
Primary: Early Virological Response — 90.0; 81.4 percentage of patients — p=0.227
Phase 2 N=140 L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors
Male Erectile Disorder · Prostate Cancer · Radiation Toxicity
Primary: International Index of Erectile Function (IIEF) — 14.62; 14.26; 11.82 units on a scale
N/A N=756 Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Number of Participants With Adverse Events and Adverse Drug Reactions — 146; 134 participants
Phase 2 N=27 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
Ductal Breast Carcinoma in Situ · Estrogen Receptor-positive Breast Cancer
Primary: Difference Between Ki-67 Labeling Index in Tissue Samples Taken at Baseline and Post-treatment — -3.4; -5.1 percentage of 300 DCIS cells